GRIN1 Antibody

What is GRIN1 and why is it important in neuroscience research?

GRIN1 encodes subunit 1 of the N-methyl-D-aspartate (NMDA) receptor, a heteromeric glutamate-gated calcium ion channel essential for synaptic function in the brain. This protein is also known by several alternative names including NMDAR1, NR1, MRD8, GluN1, and NMDA1 . NMDA receptors play crucial roles in normal brain development and function, making them critical targets for understanding neurological disorders and neurodevelopmental conditions . The GRIN1 protein has a calculated molecular weight of approximately 105 kDa, though it is typically observed at 105-120 kDa in experimental contexts .

What are the common applications for GRIN1 antibodies in research?

GRIN1 antibodies are employed across multiple experimental techniques including:

• Western Blot (WB): For protein detection and quantification

• Immunohistochemistry (IHC): For tissue localization studies

• Immunofluorescence (IF): For cellular and subcellular localization

• Immunoprecipitation (IP): For protein complex isolation

• ELISA: For quantitative protein detection

Different antibodies have varying recommended dilutions for each application. For example, the 67717-1-Ig monoclonal antibody is recommended at 1:2000-1:10000 for WB, 1:500-1:2000 for IHC, and 1:250-1:1000 for IF-P applications .

How do I determine the appropriate antibody dilution for my specific experimental system?

While manufacturers provide recommended dilution ranges, optimal concentrations should be experimentally determined for each research system. As noted in technical documentation, "It is recommended that this reagent should be titrated in each testing system to obtain optimal results" .

For establishing optimal dilutions:

• Begin with the manufacturer's recommended range

• Perform a dilution series experiment

• Evaluate signal-to-noise ratio and specificity at each dilution

• Consider sample-dependent factors that may affect antibody performance

• Document optimal conditions for reproducibility

This process is particularly important when working with new tissue types or experimental conditions not explicitly validated by the manufacturer.

What criteria should I consider when selecting between monoclonal and polyclonal GRIN1 antibodies?

Selection between monoclonal and polyclonal GRIN1 antibodies depends on research objectives:

Monoclonal antibodies (e.g., 67717-1-Ig):

• Provide high specificity to a single epitope

• Offer excellent batch-to-batch reproducibility

• Ideal for applications requiring consistent performance

• Typically raised in mouse hosts (IgG1 isotype common)

Polyclonal antibodies (e.g., 27232-1-AP):

• Recognize multiple epitopes on the target protein

• Provide potentially stronger signals by binding multiple sites

• More tolerant of minor protein denaturation or modification

• Often raised in rabbit hosts

Consider your experimental requirements: monoclonals excel in applications requiring high specificity and reproducibility, while polyclonals may offer advantages in detection sensitivity and tolerance to protein modifications.

How do I optimize antigen retrieval for GRIN1 immunohistochemistry in brain tissue samples?

Optimal antigen retrieval for GRIN1 IHC in brain tissue requires careful consideration of buffer composition and pH:

• Primary recommendation: TE buffer at pH 9.0

• Alternative approach: Citrate buffer at pH 6.0

The choice between these methods can significantly impact staining quality and should be experimentally determined based on:

• Tissue fixation method

• Fixation duration

• Sample age

• Specific brain region being examined

As indicated in technical documentation for 67717-1-Ig and 27232-1-AP antibodies, both mouse cerebellum and brain tissue have been positively validated for IHC applications using these retrieval methods .

What controls should be included when using GRIN1 antibodies for experimental validation?

Robust experimental design with GRIN1 antibodies requires the following controls:

• Positive tissue controls: Include validated positive samples such as:

  • Mouse brain tissue

  • Rat brain tissue

  • Mouse cerebellum tissue

• Negative controls:

  • Primary antibody omission control

  • Isotype control (matching the antibody's host species and isotype)

  • Non-expressing tissue (when available)

• Specificity controls:

  • Peptide competition assay using the immunizing peptide

  • GRIN1 knockout or knockdown samples when feasible

  • Multiple antibodies targeting different epitopes for cross-validation

Include these controls to distinguish specific from non-specific signals and to validate antibody performance in your experimental system.

How can GRIN1 antibodies be used to investigate NMDAR-related encephalitis mechanisms?

GRIN1 antibodies serve as valuable tools for investigating NMDAR encephalitis, a rare autoantibody-mediated neurologic disease characterized by personality changes, psychiatric symptoms, memory loss, seizures, and autonomic dysfunction .

Methodological approach:

• Patient sample analysis: Use GRIN1 antibodies in immunoblotting to detect autoantibodies against NMDA receptors in patient sera or CSF

• Genetic association studies: Investigate whether GRIN1 polymorphisms affect disease susceptibility or presentation

• Receptor trafficking analysis: Employ immunofluorescence to monitor changes in receptor localization in response to autoantibodies

• Co-immunoprecipitation: Identify binding partners and complex formation alterations in disease states

Research has shown that SNPs in GRIN1 (rs6293 in exon 6 and rs1126442 in exon 7) do not strongly affect disease susceptibility or course in patients with NMDAR encephalitis, suggesting other genetic or immunological factors are more critical .

What approaches can be used to study GRIN1 variants and their impact on NMDAR function?

Investigating GRIN1 variants requires a multidisciplinary approach combining:

• Structural analysis: Use molecular modeling to predict how variants may affect protein folding and function

• Biochemical characterization: Employ GRIN1 antibodies to assess protein expression, stability, and post-translational modifications

• Cell biology: Utilize immunofluorescence to evaluate subcellular localization and trafficking

• Electrophysiology: Measure receptor function and channel properties

• Computational modeling: Predict variant effects on protein-protein interactions

Research has identified multiple functional mechanisms by which GRIN1 variants affect NMDAR function, including:

• Protein folding defects

• Impaired subunit assembly

• Defective surface trafficking

• Altered biophysical properties

For example, variants like R217W, D227Q, G827R, E834Q and I619_G620dup prevent proper protein folding, leading to misfolded proteins unable to reach the plasma membrane .

How can smFRET combined with GRIN1 antibodies advance understanding of conformational changes in NMDA receptors?

Single-molecule fluorescence resonance energy transfer (smFRET) combined with GRIN1 antibodies offers powerful insights into NMDAR conformational dynamics:

Methodological approach:

• Epitope selection: Choose GRIN1 antibodies targeting specific domains (e.g., amino-terminal domain or agonist-binding domain)

• Fluorophore conjugation: Label antibodies with donor/acceptor fluorophores

• Receptor labeling: Use antibodies to target specific GRIN1 regions

• Conformational analysis: Measure FRET efficiency changes reflecting receptor conformational states

• Pharmacological manipulation: Assess how ligands or disease-associated mutations alter conformational dynamics

This approach has been successfully employed to study how variants like the Pro532 mutation affect GluN2 conformation and function, revealing that this residue's location at the interface of GluN1 and GluN2 ABDs is critical for receptor function .

What strategies can resolve non-specific binding issues when using GRIN1 antibodies in Western blotting?

Non-specific binding in Western blots with GRIN1 antibodies can be addressed through:

• Optimization of blocking conditions:

  • Test alternative blocking agents (BSA, non-fat milk, commercial blockers)

  • Adjust blocking duration (1-24 hours)

  • Vary blocking agent concentration (1-5%)

• Antibody dilution adjustment:

  • GRIN1 monoclonal antibody 67717-1-Ig: Test within 1:2000-1:10000 range

  • GRIN1 polyclonal antibody 27232-1-AP: Test within 1:500-1:1000 range

• Sample preparation refinement:

  • Ensure complete protein denaturation

  • Consider phosphatase inhibitors (GRIN1 is regulated by phosphorylation)

  • Optimize protein loading (10-30 μg total protein)

• Wash optimization:

  • Increase wash duration and frequency

  • Add low concentrations of detergent (0.05-0.1% Tween-20)

  • Consider high-salt wash steps

• Secondary antibody adjustment:

  • Test alternative secondary antibodies

  • Further dilute secondary antibody

  • Pre-adsorb secondary antibody against tissue lysates

How can I distinguish between GRIN1 splice variants using antibodies?

Distinguishing GRIN1 splice variants requires careful antibody selection and experimental design:

• Epitope mapping: Select antibodies targeting:

  • Conserved regions (to detect all variants)

  • Splice variant-specific sequences (for variant discrimination)

• Molecular weight verification:

  • GRIN1 typically appears at 105-120 kDa

  • Splice variants may show slight mobility differences

  • Use high-resolution SDS-PAGE (6-8% gels) for optimal separation

• Validated controls:

  • Include recombinant splice variant standards

  • Use tissues known to express specific variants

  • Consider knockdown/overexpression controls

• Complementary techniques:

  • Combine antibody-based detection with RT-PCR

  • Consider mass spectrometry for definitive isoform identification

  • Use variant-specific primers for validation

• Data analysis:

  • Perform densitometry to quantify relative expression

  • Compare results across multiple detection methods

  • Statistically analyze reproducibility across biological replicates

How should I interpret discrepancies in GRIN1 molecular weight across different experimental systems?

GRIN1 protein exhibits variable molecular weights (105-120 kDa) across different experimental systems . Consider these factors when interpreting apparent molecular weight variations:

• Post-translational modifications:

  • Phosphorylation status (particularly at Ser890 and Ser896)

  • Glycosylation patterns

  • Ubiquitination state

• Sample preparation variations:

  • Denaturation completeness

  • Reducing agent effectiveness

  • Buffer composition effects

• Gel system considerations:

  • Acrylamide percentage

  • Running buffer composition

  • Molecular weight marker calibration

• Antibody-specific factors:

  • Epitope accessibility in different conformational states

  • Recognition of specific post-translationally modified forms

  • Clone-specific detection properties

• Tissue/species-specific factors:

  • Species-specific sequence variations

  • Tissue-specific processing differences

  • Expression levels affecting detection sensitivity

When comparing across studies, consider standardizing to internal controls and using multiple antibodies targeting different GRIN1 epitopes for verification.

How can I quantitatively assess GRIN1 expression changes in disease models using antibody-based methods?

Rigorous quantification of GRIN1 expression changes requires:

• Western blot quantification:

  • Use standard curves with recombinant GRIN1 protein

  • Normalize to multiple housekeeping proteins (not just one)

  • Employ automated densitometry software

  • Analyze multiple biological replicates (minimum n=3)

  • Apply appropriate statistical tests

• Immunohistochemistry quantification:

  • Use semi-automated image analysis software

  • Establish consistent thresholding parameters

  • Quantify across multiple fields and tissue sections

  • Perform regional analysis where appropriate

  • Include experimenter blinding procedures

• Controls for validation:

  • Include positive controls (brain tissues)

  • Use negative controls (antibody omission, isotype controls)

  • Consider spike-in standards for absolute quantification

  • Validate antibody specificity in disease model context

• Complementary approaches:

  • Confirm protein changes with mRNA quantification

  • Consider mass spectrometry for unbiased validation

  • Use multiple antibodies targeting different epitopes

What considerations are important when comparing results from different GRIN1 antibody clones across studies?

When comparing results from different GRIN1 antibody clones across studies, consider:

• Epitope differences:

  • Monoclonal 67717-1-Ig: Targets GRIN1 fusion protein Ag26364

  • Monoclonal S308-48: Targets amino acids 42-361 (extracellular N-terminus)

  • Polyclonal 27232-1-AP: Targets GRIN1 fusion protein Ag26093

• Antibody class variations:

  • Monoclonal antibodies detect single epitopes

  • Polyclonal antibodies recognize multiple epitopes

  • Different host species may affect background patterns

• Validation parameters:

  • Verified applications may differ between antibodies

  • Species reactivity variations

  • Validation methodologies may not be equivalent

• Technical considerations:

  • Recommended dilutions vary significantly between products

  • Optimal buffers and conditions may differ

  • Sensitivity and dynamic range can vary substantially

• Standardization approaches:

  • Use common positive controls across studies

  • Employ absolute quantification when possible

  • Report raw data and analysis parameters

  • Consider antibody benchmarking studies

To enhance reproducibility, researchers should report detailed antibody information including catalog numbers, dilutions, incubation conditions, and validation procedures.